
Senseonics Holdings (SENS) Stock Forecast & Price Target
Senseonics Holdings (SENS) Analyst Ratings
Bulls say
Senseonics Holdings Inc. demonstrates a strong positive outlook, with projected total revenues increasing significantly from $59.7 million in 2025 to $75.6 million in 2026, and further rising to $118.4 million in 2027, up from $94.6 million. The company's anticipated ramp-up in the second half of 2025, fueled by European Union approval and a partnership with Sequel Diabetes, is expected to enhance market presence and revenue growth. Additionally, the firm’s focus on differentiated, long-term implantable glucose management technology positions it well within the diabetes management market, mainly generating its revenue from international markets.
Bears say
Senseonics Holdings Inc. anticipates that its revenues in the first half of 2025 will remain relatively flat, largely due to the transition from previous U.S. revenue streams. Despite the existing demand for long-term glucose monitoring solutions, the stagnation in revenue growth suggests challenges in market penetration and sales expansion. Furthermore, the company's reliance on international markets for the majority of its revenue raises concerns about its revenue stability and potential vulnerabilities to foreign market dynamics.
This aggregate rating is based on analysts' research of Senseonics Holdings and is not a guaranteed prediction by Public.com or investment advice.
Senseonics Holdings (SENS) Analyst Forecast & Price Prediction
Start investing in Senseonics Holdings (SENS)
Order type
Buy in
Order amount
Est. shares
0 shares